Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

Neuralstem Phase 1 Data Gives Hope In ALS

Data from the Phase 1 trial of Neuralstem's (NYSEMKT:CUR) NSI-566 in Amyotrophic Lateral Sclerosis (or "ALS") patients was presented at the 2013 American Neurology Association Meeting in October 2013 and is being published in the Annals of Neurology. While data has been previously reported on the initial trial cohort of 12 ALS subjects who received only lumbar injections, the presentation and manuscript for peer-review describe follow up data for the initial 12 subjects as well as the outcome of the final trial cohorts, which consisted of six patients receiving five cervical injections with half of those patients having previously received 10 lumbar injections.

This is important, because the earlier cohorts in the study were safety assessments. The...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details